About Ken Kobayashi
Dr. Kobayashi is an accomplished oncologist, clinical pharmacologist, and senior global life sciences executive. He has a deep background as a clinician scientist, regulator, scientific diplomat and drug developer across the US, Europe, Latin America, and Japan/Asia. As a senior executive in top-tier pharmaceutical companies including Pfizer, Daiichi Sankyo, AstraZeneca, Janssen, and Novartis, he has successfully overseen the introduction of more than 28 investigational agents and been directly involved with 60 programs, including in the areas of signal transduction inhibitors, epigenetic modifiers, and inflammation/immunotherapy. His experience also includes roles at the National Cancer Institute and the Food and Drug Administration. He is active in the climate change advocacy space, especially as it intersects with cancer outcomes.
He is currently studying for a Master’s degree in Public Health at the University of California, Berkeley. He received his AB from Washington University, St. Louis, MO. his MD from Northwestern University Medical School, Chicago, IL, and trained in internal medicine at Northwestern Memorial Hospital and in medical oncology at the University of Chicago, Chicago IL. He now works in the biotech space and is President of Small Woods Biopharma Consulting, LLC.
